Skip to main content

Table 2 Thrombosis/thromboembolism and bleeding events in MPN

From: Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

 

All Pts

PV

ET

PMF

Post-PV-MF

Post-ET-MF

MPN-U

p value#

Thrombosis/thromboembolisma; n (%)

147

(33.6)

n = 438

54

(38.9)

n = 139

33

(25)

n = 132

34

(31.2)

n = 109

13

(61.9)

n = 21

8

(42.1)

n = 19

5

(27.8)

n = 18

0.0120

 DVT; n (%)

46

(31.5)

n = 146

15

(27.8)

n = 54

10

(30.3)

n = 33

11

(33.3)

n = 33

4

(30.8)

n = 13

3

(37.5)

n = 8

3

(60)

n = 5

0.7781

 ACS; n (%)

41

(27.7)

n = 148

15

(27.8)

n = 54

12

(35.3)

n = 34

7

(20.6)

n = 34

4

(30.8)

n = 13

2

(25)

n = 8

1

(20)

n = 5

0.8439

 Stroke; n (%)

28

(19.3)

n = 145

13

(24.5)

n = 53

7

(21.2)

n = 33

7

(21.2)

n = 33

0

(0)

n = 13

0

(0)

n = 8

1

(20)

n = 5

0.2714

 SVT; n (%)

22

(15.2)

n = 145

3

(5.7)

n = 53

6

(18.2)

n = 33

6

(18.2)

n = 33

4

(30.8)

n = 13

0

(0)

n = 8

3

(60)

n = 5

0.0083

Bleedinga, n (%)

36

(8.2)

n = 437

13

(9.4)

n = 139

5

(3.8)

n = 133

10

(9.3)

n = 108

4

(19.1)

n = 21

1

(5.3)

n = 19

3

(17.7)

n = 17

0.0586

 Upper GI-Tract-Bleeding; n (%)

20

(55.6)

n = 36

7

(53.9)

n = 13

3

(69)

n = 5

6

(60)

n = 10

3

(75)

n = 4

0

(0)

n = 1

1

(33.3)

n = 3

0.8748

 Postinterventional; n (%)

4

(11.1)

n = 36

3

(23.1)

n = 13

0

(0)

n = 5

0

(0)

n = 10

0

(0)

n = 4

1

(100)

n = 1

0

(0)

n = 3

0.0958

 CNS; n (%)

3

(8.3)

n = 36

0

(0)

n = 13

0

(0)

n = 5

3

(30)

n = 10

0

(0)

n = 4

0

(0)

n = 1

0

(0)

n = 3

0.1725

  1. Pts patients, DVT deep vein thrombosis, ACS acute coronary syndrome, SVT splanchnic vein thrombosis, CNS central nervous system
  2. #In Fisher’s exact test
  3. aLife-time events